Intracranial Hemorrhage Due to Potential Rupture of an Arteriovenous Malformation after BNT162b2 COVID-19 mRNA Vaccination in a Young Korean Woman: Case Report

Kim, Byoung-Hoon; Yoo, Myung Chul

doi:10.3390/vaccines10030362

Cited by 6 publications

(8 citation statements)

References 24 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, neurological manifestations (6%) had been reviewed; headache was the most common manifestation. In terms of cardiac manifestation, it made up 5% of all complications [21]. When assessing the complications following the infection with COVID-19, 66% of participants had no complications at all; however, like the vaccine complications, pulmonary complications were the most noted (17%).…”

Section: Discussionmentioning

confidence: 99%

Complications Following COVID-19 Infection or Vaccination in Libyan International Medical University Students and Their Families

Alfituri,

Alasbily

2024

Alq J Med App Sci

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) caused by a novel strain of coronavirus belonging to the genus Beta coronavirus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged as a major pandemic worldwide. This contagious virus had spread in many different forms, and patients have demonstrated a wide range of symptoms, ranging from moderate to severe illness. This study aims to highlight the important associations between SARS-CoV-2 infection, vaccination, and possible complications at the Libyan International Medical University, Benghazi. This cross-sectional survey was conducted among students and their families at Libyan International Medical University in Benghazi, Libya. Among the 100 participants, 72% were between the ages of 18 and 39. Up to (59%) of participants were men. As for the infection with COVID-19, 77% of participants were infected. Most of the participants had no chronic diseases (69%); however, the most common chronic disease was diabetes mellitus (13%). 82% of participants were vaccinated; the most common types of vaccines administered were Sinopharm and Sputnik V (24%). Following vaccination, 71% of participants had no COVID-19 infection, while 29% did get the infection. Regarding this study, after COVID-19 infection, 66% of participants had no complications; however, 17% had pulmonary complications, which was the most common complication among the participants. As for the complications following the vaccination, 81% of participants had none, while there were pulmonary and neurological complications in 7–6%. The results of the study showed that the most frequent complications noticed among the participants following the COVID-19 infection and vaccination were pulmonary and neurological complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Complications Following COVID-19 Infection or Vaccination in Libyan International Medical University Students and Their Families

Alfituri,

Alasbily

2024

Alq J Med App Sci

View full text Add to dashboard Cite

show abstract

“…To our knowledge, ten cases of intracranial hemorrhage after the Pfizer-BioNTech COVID-19 mRNA (BNT162b2) vaccine have been reported in the literature across four different studies [ 3 , 6 - 8 ]. In one case, ruptured arteriovenous malformation caused intracranial hemorrhage [ 3 ]. A ruptured cerebral aneurysm led to intracranial hemorrhage in five cases.…”

Section: Discussionmentioning

confidence: 99%

“…The vaccination program represents the most effective strategy for reducing the impact of the disease and ending the pandemic [ 2 ]. The European Medicines Agency has approved five vaccines, including the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) [ 3 ]. Although there is a consensus that the benefits of vaccines outweigh their complications, some serious complications have arisen [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Intracranial Hemorrhage After Pfizer-BioNTech (BNT162b2) mRNA COVID-19 Vaccination: A Case Report

Yangi¹,

Demir²,

Uzunkol³

2023

Cureus

View full text Add to dashboard Cite

The Coronavirus 2019 (COVID-19) pandemic has affected over 700 million people worldwide and caused nearly 7 million deaths. Vaccines currently developed or in development are the most effective tools for curbing the pandemic and mitigating its impacts. In Turkey, inoculation with the Pfizer-BioNTech COVID-19 vaccine (BNT162b2, also known as tozinameran) has been approved.We report a 56-year-old female patient with underlying essential hypertension who experienced intracranial hemorrhage after receiving her first dose of tozinameran. The patient underwent immediate surgical evacuation of the hematoma, during which a left middle cerebral artery bifurcation aneurysm was macroscopically identified and clipped. The patient was pronounced deceased on the second postoperative day. This is the second case of intracranial hemorrhage following tozinameran administration caused by a ruptured middle cerebral artery bifurcation aneurysm. Upon analyzing the case, there might be a connection between the vaccine's potential immune-triggering effect on hemodynamic patterns and the rupture of the previously unknown cerebral aneurysm. However, these severe complications do not justify avoiding vaccines; further studies are needed. This study emphasizes the need for increased vigilance in patients with underlying systemic comorbidities who have recently been vaccinated and to share our insights into the potential relationship between tozinameran and intracranial hemorrhage.

show abstract

“…New-onset seizures and epilepsy evidence tableCerebrovascular events (CVEs) such as stroke, intracerebral hemorrhage, or transient ischemic attack comprise a significant burden of disease worldwide, with an estimated 800,000 CVEs occurring each year in the United States and the incidence of events sharply rising with age 100,101. CVEs are associated with multiple well-studied risk factors including hypertension, diabetes mellitus, and tobacco use102 ; therefore, studies assessing the direct relationship between COVID-19 vaccines and CVEs are limited.Most descriptions of CVEs have been published as case reports (►Table 6) [103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122]. Across 14 articles describing 17 cases,[109][110][111][112][113][114][115][116][117][118][119][120][121][122] 12/17 (76.9%) patients had significant CVE risk factors prior to presentation including hypertension, hyperlipidemia, diabetes mellitus, or previous stroke or myocardial infarction.…”

mentioning

confidence: 99%

“…CVEs are associated with multiple well-studied risk factors including hypertension, diabetes mellitus, and tobacco use102 ; therefore, studies assessing the direct relationship between COVID-19 vaccines and CVEs are limited.Most descriptions of CVEs have been published as case reports (►Table 6) [103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122]. Across 14 articles describing 17 cases,[109][110][111][112][113][114][115][116][117][118][119][120][121][122] 12/17 (76.9%) patients had significant CVE risk factors prior to presentation including hypertension, hyperlipidemia, diabetes mellitus, or previous stroke or myocardial infarction. Given the multifactorial nature of CVEs and the wide variety in presentations among selected reports, the specific relationship between COVID-19 vaccinations and CVEs remains weak.…”

mentioning

confidence: 99%

Neurological Considerations with COVID-19 Vaccinations

et al. 2023

View full text Add to dashboard Cite

The benefits of coronavirus disease 2019 (COVID-19) vaccination significantly outweigh its risks on a public health scale, and vaccination has been crucial in controlling the spread of SARS-CoV-2. Nonetheless, several reports of adverse events following vaccination have been published.To summarize reports to date and assess the extent and quality of evidence regarding possible serious adverse neurological events following COVID-19 vaccination, focusing on Food and Drug Administration (FDA)-approved vaccines in the United States (BNT162b2, mRNA-1273, and Ad26.COV2.S).A review of literature from five major electronic databases (PubMed, Medline, Embase, Cochrane Library, and Google Scholar) was conducted between December 1, 2020 and June 5, 2022. Articles included in the review were systematic reviews and meta-analysis, cohort studies, retrospective studies, case–control studies, case series, and reports. Editorials, letters, and animal studies were excluded, since these studies did not include quantitative data regarding adverse side effects of vaccination in human subjects.Of 149 total articles and 97 (65%) were case reports or case series. Three phase 3 trials initially conducted for BNT162b2, MRNA-1273, and Ad26.COV2.S were included in the analysis.The amount and quality of evidence for possible neurological adverse events in the context of FDA-approved COVID-19 vaccinations is overall low tier. The current body of evidence continues to suggest that COVID-19 vaccinations have a high neurological safety profile; however, the risks and benefits of vaccination must continue to be closely monitored.

show abstract

Intracranial Hemorrhage Due to Potential Rupture of an Arteriovenous Malformation after BNT162b2 COVID-19 mRNA Vaccination in a Young Korean Woman: Case Report

Cited by 6 publications

References 24 publications

Complications Following COVID-19 Infection or Vaccination in Libyan International Medical University Students and Their Families

Complications Following COVID-19 Infection or Vaccination in Libyan International Medical University Students and Their Families

Intracranial Hemorrhage After Pfizer-BioNTech (BNT162b2) mRNA COVID-19 Vaccination: A Case Report

Neurological Considerations with COVID-19 Vaccinations

Contact Info

Product

Resources

About